Ignite Creation Date:
2025-12-25 @ 12:43 AM
Ignite Modification Date:
2025-12-25 @ 10:55 PM
Study NCT ID:
NCT06821867
Status:
COMPLETED
Last Update Posted:
2025-08-07
First Post:
2025-01-30
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Efficacy and Safety of PN+HA (NEWEST) for the Improvement of Skin Hydration
Sponsor:
Mastelli S.r.l
Organization:
Study Overview
Official Title:
A Post-market, Monocentric, Interventional, Single-arm, Confirmative Clinical Investigation to Evaluate the Performance and the Safety of PN+HA (NEWEST) for the Improvement of Skin Hydration
Status:
COMPLETED
Status Verified Date:
2025-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a post-market, monocentric, interventional, single-arm, confirmative clinical investigation to evaluate the performance and the safety of PN+HA (NEWEST) for the improvement of skin hydration.
Each Subject, after signing the Informed Consent Form (ICF), will enter into a screening/baseline phase during which the baseline tests will be conducted. The Subject can be treated immediately after signing the ICF.
For each Subject, 5 visits will be planned during which several assessments will be performed as described in the Flowchart:
* V0 (Screening/baseline): Day 0, when the first IP injection will be performed;
* V1: 2 weeks ± 7 days from V0, when the second IP injection will be performed;
* V2: 2 weeks ± 7 days from V1, when the third IP injection will be performed (End Of Treatment/EOT);
* V3: maximum 4 months from V0 and 2 months after the last IP injection (V2);
* V4: maximum 6 months form V0 and 4 months after the last IP injection (V2).
At V0, the Investigator will collect demographic data (e.g., gender, age, skin phototype according to Fitzpatrick's classification), medical history (e.g., history of autoimmune disease, diabetes, etc.), drug allergy history of the enrolled Subject.
At V0, V1, and V2 according to the instructions for use (IFU), the enrolled Subjects will be treated with PN+HA in maximum 2 areas of the face, or 1 area of the face plus neck/décolleté/back of the hands, making sure that at least 10 areas of face, neck, décolleté and back of the hands will be reached.
Local anesthetics containing lidocaine may be used in order to guarantee the necessary comfort to the Subject.
Performance will be evaluated by the Investigator using the Global Aesthetic Improvement Scale (GAIS) at each visit. The GAIS will be independently completed by the Investigator and the Subject. Photographs with a 2D camera will be taken at each visit. Skin hydration will be assessed by using the MoistureMeterEpiD (at least three measurements will be obtained per each area treated) at each visit.
Skin elasticity will be evaluated using the ElastiMeter (at least three measurements will be obtained per each area treated) at each visit.
Skin turgor will be assessed by the Investigator using a 5-Likert scale at each visit.
At V0, V1 and V2 after injection, the Investigator will record Subjects' pain intensity using the Numerical Rating Scale (NRS).
Subject satisfaction with treatment will be evaluated with a 5-point Likert Scale at V3 and EOS visit (V4).
Safety will include evaluation of possible cutaneous reactions at each visit. Adverse events, concomitant medications, and device deficiencies will be monitored during the entire duration of the study.
Each Subject, after signing the Informed Consent Form (ICF), will enter into a screening/baseline phase during which the baseline tests will be conducted. The Subject can be treated immediately after signing the ICF.
For each Subject, 5 visits will be planned during which several assessments will be performed as described in the Flowchart:
* V0 (Screening/baseline): Day 0, when the first IP injection will be performed;
* V1: 2 weeks ± 7 days from V0, when the second IP injection will be performed;
* V2: 2 weeks ± 7 days from V1, when the third IP injection will be performed (End Of Treatment/EOT);
* V3: maximum 4 months from V0 and 2 months after the last IP injection (V2);
* V4: maximum 6 months form V0 and 4 months after the last IP injection (V2).
At V0, the Investigator will collect demographic data (e.g., gender, age, skin phototype according to Fitzpatrick's classification), medical history (e.g., history of autoimmune disease, diabetes, etc.), drug allergy history of the enrolled Subject.
At V0, V1, and V2 according to the instructions for use (IFU), the enrolled Subjects will be treated with PN+HA in maximum 2 areas of the face, or 1 area of the face plus neck/décolleté/back of the hands, making sure that at least 10 areas of face, neck, décolleté and back of the hands will be reached.
Local anesthetics containing lidocaine may be used in order to guarantee the necessary comfort to the Subject.
Performance will be evaluated by the Investigator using the Global Aesthetic Improvement Scale (GAIS) at each visit. The GAIS will be independently completed by the Investigator and the Subject. Photographs with a 2D camera will be taken at each visit. Skin hydration will be assessed by using the MoistureMeterEpiD (at least three measurements will be obtained per each area treated) at each visit.
Skin elasticity will be evaluated using the ElastiMeter (at least three measurements will be obtained per each area treated) at each visit.
Skin turgor will be assessed by the Investigator using a 5-Likert scale at each visit.
At V0, V1 and V2 after injection, the Investigator will record Subjects' pain intensity using the Numerical Rating Scale (NRS).
Subject satisfaction with treatment will be evaluated with a 5-point Likert Scale at V3 and EOS visit (V4).
Safety will include evaluation of possible cutaneous reactions at each visit. Adverse events, concomitant medications, and device deficiencies will be monitored during the entire duration of the study.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: